Gefitinib in Pretreated Non–Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC
Federico Cappuzzo, Vanesa Gregorc, Elisa Rossi et al. · Journal of Clinical Oncology · 2003
PURPOSE: To evaluate the correlation between HER2 expression and gefitinib (ZD 1839, Iressa; AstraZeneca, London, United Kingdom) efficacy in terms of response rate, time to progression (TTP), and overall survival (OS) time. PATIENTS AND METHODS: Patients with pretreated advanced non-small-cell lung cancer (NSCLC) received gefitinib at a daily dose of 250 mg until disease progression. Tumor tissue specimens obtained at the time of primary diagnosis were collected to determine HER2/epidermal growth factor receptor (EGFR) status by immunohistochemistry. RESULTS: From February 2001 to June 2002, 63 consecutive patients were enrolled onto the study. The overall disease control rate was 58.7% (partial response [PR], 15.9%; stable disease [SD], 42.8%), median TTP was 3.3 months, and median OS was 4.1 months. Among the 43 patients in whom EGFR/HER2 status was determined, we observed six PRs (14%) and 18 SDs (42%). Disease control, including PR and SD, was 40% in the 15 patients overexpressing HER2 and 64.3% in the 28 patients not overexpressing HER2 (P =.126). No difference was found between the two groups in terms of TTP (3.5 v 3.7 months, respectively) and OS (5.7 v 6.8 months, respectively). In addition, we did not find any difference in TTP, OS, toxicity, and symptom outcome in the group of patients overexpressing both HER2 and EGFR compared with patients who had no overexpression of HER2 CONCLUSION: According to these data, efficacy, toxicity, and symptom outcome in patients with NSCLC treated with gefitinib do not seem to be related to HER2 expression.
Cited by 212 works. doi:10.1200/jco.2003.01.039
Authors
- Federico Cappuzzo
- Vanesa Gregorc
- Elisa Rossi
- Alessandra Cancellieri
- Elisabetta Magrini
- Carlo Terenzio Paties
- Giovanni Luca Ceresoli
- Laura Lombardo
- Stefania Bartolini
- Cesare Calandri
- Marisa De Rosa
- Eugenio Villa
- Lucio Crinò
References
- Nonparametric Estimation from Incomplete Observations
- Nonparametric Estimation from Incomplete Observations
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Epidermal Growth Factor
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- GROWTH FACTOR RECEPTOR TYROSINE KINASES
- BindingDB Entry 50022499: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
- Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition
- Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
- The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy